The European Commission’s Artificial Intelligence Act
This explainer summarizes the European Commission's proposal to regulate “high-risk” AI use cases and briefly discusses its implications.
Key Takeaways
To address the variety of risks associated with societal adoption of AI, the European Commission has proposed a set of regulations that promote the uptake of AI and try to mitigate or prevent harms associated with certain uses of the technology.
Under the proposal, developers of high-risk AI systems will need to perform both pre-deployment conformity assessments and post-market monitoring analysis to demonstrate that their systems meet all requirements in the AI Act (AIA)’s risk framework.
The AIA expressly prohibits the use of AI for subliminal distortion of a person’s behavior that may cause physical or mental harm; exploiting vulnerabilities of specific groups of people like the young, the elderly, or persons with disabilities; social scoring that may lead to unjustified or disproportionate detrimental treatment; and real-time remote biometric identification in publicly accessible spaces by law enforcement (except for specific actions like searching for missing persons or counterterrorism operations).
Executive Summary
Recent advances in artificial intelligence (AI) have led to excitement about important scientific discoveries and technological innovations. Increasingly, however, researchers in AI safety, ethics, and other disciplines are identifying risks in how AI technologies are developed, deployed, and governed. Academics, policymakers, and technologists have called for more proactive measures to tackle risks associated with AI and its applications. These range from voluntary frameworks to supranational legislation. Legislative action is on the rise. The world’s first legal framework for AI was unveiled on April 21, 2021, when the European Commission published a comprehensive proposal to regulate “high-risk” AI use cases.
Related Publications
Toward Responsible AI in Health Insurance Decision-Making
This brief proposes governance mechanisms for the growing use of AI in health insurance utilization review.
This brief proposes governance mechanisms for the growing use of AI in health insurance utilization review.
Response to OSTP's Request for Information on Accelerating the American Scientific Enterprise
Stanford scholars respond to a federal RFI on scientific discovery, calling for the government to support a new “team science” academic research model for AI-enabled discovery.
Stanford scholars respond to a federal RFI on scientific discovery, calling for the government to support a new “team science” academic research model for AI-enabled discovery.
Response to FDA's Request for Comment on AI-Enabled Medical Devices
Stanford scholars respond to a federal RFC on evaluating AI-enabled medical devices, recommending policy interventions to help mitigate the harms of AI-powered chatbots used as therapists.
Stanford scholars respond to a federal RFC on evaluating AI-enabled medical devices, recommending policy interventions to help mitigate the harms of AI-powered chatbots used as therapists.
Russ Altman’s Testimony Before the U.S. Senate Committee on Health, Education, Labor, and Pensions
In this testimony presented to the U.S. Senate Committee on Health, Education, Labor, and Pensions hearing titled “AI’s Potential to Support Patients, Workers, Children, and Families,” Russ Altman highlights opportunities for congressional support to make AI applications for patient care and drug discovery stronger, safer, and human-centered.
In this testimony presented to the U.S. Senate Committee on Health, Education, Labor, and Pensions hearing titled “AI’s Potential to Support Patients, Workers, Children, and Families,” Russ Altman highlights opportunities for congressional support to make AI applications for patient care and drug discovery stronger, safer, and human-centered.